AELIS.PA stock +26.83% to €1.56 (23 Mar 2026): recruitment lifts Phase 2 outlook

AELIS.PA stock led today’s top gainers on EURONEXT, rising 26.83% to €1.56 as the company confirmed active patient recruitment in France, Italy and Spain for its Phase 2b programme. The surge came on volume of 127530.00 shares and left the share price at the session high. We view the move as a catalyst-driven rally tied to clinical progress rather than fundamental earnings improvement. The market closed with Aelis Farma SA among the best performers in the Healthcare/Biotechnology group in Europe.

Price action and drivers: AELIS.PA stock

AELIS.PA stock jumped 26.83% intraday to €1.56, from an open of €1.29 and previous close €1.23. Trading volume of 127530.00 was roughly 1.92 times average volume, signalling strong attention from investors.

The immediate driver was the company update that recruitment is underway across France, Italy and Spain for the Phase 2b trial of AEF0117, which market participants interpret as reducing execution risk. See the company update on Investing.com for details source.

Fundamentals and valuation: AELIS.PA stock analysis

Aelis Farma is a small-cap biotechnology company (Market Cap €21,198,136.00) focused on CB1 pathway modulators. Trailing metrics remain loss-making: EPS -0.60, PE -2.59, and Price/Book approximately 3.48, reflecting early-stage R&D funding and limited revenues.

Balance-sheet strength is mixed: cash per share €0.79, current ratio 3.18, and debt-to-equity 1.13. These figures suggest liquidity to run trials, but elevated leverage versus peers increases execution risk for clinical timelines.

Technicals and volume: AELIS.PA stock technicals

Technicals show momentum: RSI 64.20 and CCI 214.45 (overbought) after the jump, with MACD histogram turning positive. The 50-day average price is €1.36 and the 200-day average is €1.19, both below today’s close, indicating recent trend strength.

On-chain volume indicators confirm the move: OBV rose and relative volume was 1.92, so the price advance is backed by higher-than-normal buying interest. Short-term traders should note ATR 0.11 and the potential for profit-taking after a sharp spike.

Meyka AI rates AELIS.PA with a score out of 100

Meyka AI rates AELIS.PA with a score of 64.62 out of 100 — Grade B, Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

The internal company rating snapshot (23 Mar 2026) also shows mixed signals: a model-based DCF score that reads bullish, while profitability metrics and leverage push some sub-scores lower. Grades are informational and not financial advice.

Meyka AI’s forecast and price targets: AELIS.PA stock forecast

Meyka AI’s forecast model projects a 12-month fair value of €2.75, versus the current price of €1.56, implying an upside of 76.28%. This target aligns with the platform price/fair-value metric of roughly €2.75 and assumes successful enrolment and no material trial delays.

Forecasts are model-based projections and not guarantees. We also flag a nearer-term scenario where clinical or regulatory setbacks could push the share back toward the year-to-date low near €0.67.

Catalysts and risks: AELIS.PA stock outlook

Near-term catalysts: continued recruitment updates, interim safety readouts, the upcoming earnings/operational update cycle (earnings announcement scheduled 30 Mar 2026), and any partnership or licensing news. Positive trial milestones could sustain the rally.

Key risks: negative trial outcomes, funding dilution risk given R&D burn, and sector-wide sentiment weakness in Healthcare. The stock’s small market cap and low liquidity increase volatility and execution risk for longer-term investors.

Final Thoughts

AELIS.PA stock delivered a clear top-gainer performance on 23 Mar 2026, rising 26.83% to €1.56 after the company confirmed active recruitment in major European sites. The move is catalyst-driven and reflects improved execution visibility for the Phase 2b AEF0117 programme. Fundamentals remain early-stage: EPS -0.60, PE -2.59, Price/Book 3.48, and Market Cap €21,198,136.00. Our technical read shows momentum but short-term overbought signals. Meyka AI’s forecast model projects a 12-month fair value of €2.75, implying an upside of 76.28% versus today’s price; forecasts are model-based projections and not guarantees. Traders should track recruitment progress, the earnings update on 30 Mar 2026, and volume confirmation before increasing exposure. For continuing coverage and live alerts see our AELIS page on Meyka AI Meyka stock page and broader market context on Investing.com economic calendar.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.